Kite
This sponsor has funded 3 studies across 10 countries.
| EU PAS ID | Status | RMP requirement | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|---|
| 32539 | Ongoing | EU RMP category 1 | Long-term, Non-interventional Study of Recipients of Yescarta® for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Primary... | Yes | No |
| 45813 | Planned | EU RMP category 1 | Long-term, Non-interventional Study of Recipients of Tecartus for Treatment of Adult Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Yes | No |
| 104052 | Ongoing | EU RMP category 3 | Tecartus Survey: Quantitative Testing of Health Care Professional Knowledge About Tecartus® Risk Minimisation Measures | Yes | No |
PAS by Risk Management Plan (RMP) requirement
Kite
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Kite
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Kite
10 Study countries specified are the following:
- Czechia
- France
- Germany
- Italy
- Netherlands
- Poland
- Portugal
- Spain
- Switzerland
- United Kingdom